How FDA Failures Contributed to the Opioid Crisis
Dados Bibliográficos
| ID | 15744277 |
|---|---|
| Autores | Andrew Kolodny (Brandeis University, autor correspondente) |
| Ano | 2020 |
| Volume | 22 |
| Fascículo | 8 |
| Páginas | E743-750 |
| Data de publicação | 2020-09-01 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | The AMA Journal of Ethic (JOURNAL) |
| Identificadores do periódico | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Editora | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/amajethics.2020.743 |
| PMID | 32880367 |
| OpenAlex | W3046557358 |
| Idioma | EN |
| Citações recebidas | 8 |
| Referências citadas | 4 |
Over the past 25 years, pharmaceutical companies deceptively promoted opioid use in ways that were often neither safe nor effective, contributing to unprecedented increases in prescribing, opioid use disorder, and deaths by overdose. This article explores regulatory mistakes made by the US Food and Drug Administration (FDA) in approving and labeling new analgesics. By understanding and correcting these mistakes, future public health crises caused by improper pharmaceutical marketing might be prevented
Business · Opioid · Medicine · Opioid Use Disorder Treatment · Pain Management and Opioid Use · Prenatal Substance Exposure Effects · Internal Medicine
The i-frame and the s-frame
"The Politics of Pain"
French Judges’ Beliefs About Addiction
Purdue's development of abuse-deterrent formulation opioids as a response to market competition
False Hope and Fictitious Patents
Vaccine Hesitancy and the Concept of Trust
How FDA Failures Contributed to the Opioid Crisis
With a Picc line, you never miss”
| Obras citantes distintas | 8 |
|---|---|
| Citações por ano | 1,33 |
| Intervalo de citações | 2020 - 2026 (7) |
| Velocidade de citação | current |
| Altamente citado | Não |
| Tipos de citação | Neutras: 8 |